The Ministry of Health, Labour and Welfare of Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL injection for IV infusion every four weeks), Eli Lilly and Company’s (NYSE: LLY) treatment for early symptomatic Alzheimer’s disease (AD). This includes patients with…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has filed for regulatory approval to launch a Phase 1/2a clinical trial for ARO-INHBE, its investigational RNA interference (RNAi) therapeutic aimed at treating obesity. The company also plans to seek regulatory…
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted it three Rare Pediatric Disease Designations (RPDD). These designations cover…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the World Health Organization (WHO) has included dual-stain cytology testing in its updated cervical cancer prevention guidelines. The Roche CINtec® PLUS Cytology test is currently the only FDA-approved and CE-marked dual-stain test…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for their Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2). This…
Ipsen (Euronext: IPN; ADR: IPSEY) has announced that the European Commission has granted conditional approval for Iqirvo® (elafibranor) 80mg tablets. Iqirvo is approved for the treatment of primary biliary cholangitis (PBC) in adults, either in combination with ursodeoxycholic acid (UDCA)…
Elanco Animal Health Incorporated (NYSE: ELAN) has announced that the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a once-daily oral JAK inhibitor for the control of pruritus (itching) caused by allergic dermatitis and atopic dermatitis in dogs 12…
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell…
AstraZeneca’s Fasenra (benralizumab) has received U.S. approval for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially fatal immune-mediated vasculitis that can damage multiple organs. This approval from the U.S. Food and Drug Administration (FDA) is…
FluMist has become the first self-administered influenza vaccine approved in the US. This needle-free nasal spray can now be self-administered by adults up to 49 years old or given by a parent or caregiver to children aged 2-17. The US…
Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate replacement therapy being developed to treat phosphomannomutase 2-congenital disorder of…
Novartis announced today that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and…
